SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-020777
Filing Date
2017-11-01
Accepted
2017-11-01 16:04:43
Documents
47
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10Q fate-10q_20170930.htm 10-Q 1289590
2 EX-31.1 fate-ex311_6.htm EX-31.1 9827
3 EX-32.1 fate-ex321_9.htm EX-32.1 4813
  Complete submission text file 0001564590-17-020777.txt   4934538

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT fate-20170930.xml EX-101.INS 957721
5 XBRL TAXONOMY EXTENSION SCHEMA fate-20170930.xsd EX-101.SCH 42539
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20170930_cal.xml EX-101.CAL 42411
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20170930_def.xml EX-101.DEF 187024
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20170930_lab.xml EX-101.LAB 345231
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20170930_pre.xml EX-101.PRE 268200
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 171168926
SIC: 2836 Biological Products, (No Diagnostic Substances)